Carl Zeiss Meditec AG (AFX.F) Competitors

Bayer (ETR:BAYN) and Carl Zeiss Meditec AG (AFX.F) (ETR:AFX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Bayer and Carl Zeiss Meditec AG (AFX.F)'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bayer and Carl Zeiss Meditec AG (AFX.F), as provided by MarketBeat.

Carl Zeiss Meditec AG (AFX.F) has a consensus price target of €102.25, indicating a potential downside of 13.86%. Given Carl Zeiss Meditec AG (AFX.F)'s higher probable upside, analysts clearly believe Carl Zeiss Meditec AG (AFX.F) is more favorable than Bayer.

Earnings & Valuation

This table compares Bayer and Carl Zeiss Meditec AG (AFX.F)'s gross revenue, earnings per share (EPS) and valuation.

Carl Zeiss Meditec AG (AFX.F) has lower revenue, but higher earnings than Bayer. Bayer is trading at a lower price-to-earnings ratio than Carl Zeiss Meditec AG (AFX.F), indicating that it is currently the more affordable of the two stocks.

Dividends

Bayer pays an annual dividend of €2.80 per share and has a dividend yield of 6.6%. Carl Zeiss Meditec AG (AFX.F) pays an annual dividend of €0.65 per share and has a dividend yield of 0.5%. Bayer pays out -49.0% of its earnings in the form of a dividend. Carl Zeiss Meditec AG (AFX.F) pays out 48.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bayer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Carl Zeiss Meditec AG (AFX.F) beats Bayer on 6 of the 9 factors compared between the two stocks.

Siemens Healthineers (ETR:SHL) and Carl Zeiss Meditec AG (AFX.F) (ETR:AFX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Siemens Healthineers and Carl Zeiss Meditec AG (AFX.F)'s net margins, return on equity and return on assets.

Dividends

Siemens Healthineers pays an annual dividend of €0.80 per share and has a dividend yield of 2.1%. Carl Zeiss Meditec AG (AFX.F) pays an annual dividend of €0.65 per share and has a dividend yield of 0.5%. Siemens Healthineers pays out 54.1% of its earnings in the form of a dividend. Carl Zeiss Meditec AG (AFX.F) pays out 48.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Siemens Healthineers and Carl Zeiss Meditec AG (AFX.F), as provided by MarketBeat.

Siemens Healthineers currently has a consensus price target of €42.37, indicating a potential upside of 11.11%. Carl Zeiss Meditec AG (AFX.F) has a consensus price target of €102.25, indicating a potential downside of 13.86%. Given Siemens Healthineers' stronger consensus rating and higher probable upside, research analysts clearly believe Siemens Healthineers is more favorable than Carl Zeiss Meditec AG (AFX.F).

Earnings & Valuation

This table compares Siemens Healthineers and Carl Zeiss Meditec AG (AFX.F)'s gross revenue, earnings per share (EPS) and valuation.

Siemens Healthineers has higher revenue and earnings than Carl Zeiss Meditec AG (AFX.F). Siemens Healthineers is trading at a lower price-to-earnings ratio than Carl Zeiss Meditec AG (AFX.F), indicating that it is currently the more affordable of the two stocks.

Summary

Siemens Healthineers beats Carl Zeiss Meditec AG (AFX.F) on 7 of the 10 factors compared between the two stocks.

Carl Zeiss Meditec AG (AFX.F) (ETR:AFX) and Fresenius Medical Care AG & Co. KGaA (FME.F) (ETR:FME) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Carl Zeiss Meditec AG (AFX.F) and Fresenius Medical Care AG & Co. KGaA (FME.F)'s net margins, return on equity and return on assets.

Dividends

Carl Zeiss Meditec AG (AFX.F) pays an annual dividend of €0.65 per share and has a dividend yield of 0.5%. Fresenius Medical Care AG & Co. KGaA (FME.F) pays an annual dividend of €1.20 per share and has a dividend yield of 1.7%. Carl Zeiss Meditec AG (AFX.F) pays out 48.7% of its earnings in the form of a dividend. Fresenius Medical Care AG & Co. KGaA (FME.F) pays out 27.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Fresenius Medical Care AG & Co. KGaA (FME.F) is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a summary of recent ratings for Carl Zeiss Meditec AG (AFX.F) and Fresenius Medical Care AG & Co. KGaA (FME.F), as reported by MarketBeat.com.

Carl Zeiss Meditec AG (AFX.F) currently has a consensus price target of €102.25, indicating a potential downside of 13.86%. Fresenius Medical Care AG & Co. KGaA (FME.F) has a consensus price target of €83.29, indicating a potential upside of 21.34%. Given Fresenius Medical Care AG & Co. KGaA (FME.F)'s stronger consensus rating and higher probable upside, analysts plainly believe Fresenius Medical Care AG & Co. KGaA (FME.F) is more favorable than Carl Zeiss Meditec AG (AFX.F).

Earnings & Valuation

This table compares Carl Zeiss Meditec AG (AFX.F) and Fresenius Medical Care AG & Co. KGaA (FME.F)'s revenue, earnings per share (EPS) and valuation.

Fresenius Medical Care AG & Co. KGaA (FME.F) has higher revenue and earnings than Carl Zeiss Meditec AG (AFX.F). Fresenius Medical Care AG & Co. KGaA (FME.F) is trading at a lower price-to-earnings ratio than Carl Zeiss Meditec AG (AFX.F), indicating that it is currently the more affordable of the two stocks.

Summary

Fresenius Medical Care AG & Co. KGaA (FME.F) beats Carl Zeiss Meditec AG (AFX.F) on 8 of the 10 factors compared between the two stocks.

Carl Zeiss Meditec AG (AFX.F) (ETR:AFX) and MERCK Kommanditgesellschaft auf Aktien (MRK.F) (ETR:MRK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Valuation and Earnings

This table compares Carl Zeiss Meditec AG (AFX.F) and MERCK Kommanditgesellschaft auf Aktien (MRK.F)'s top-line revenue, earnings per share (EPS) and valuation.

MERCK Kommanditgesellschaft auf Aktien (MRK.F) has higher revenue and earnings than Carl Zeiss Meditec AG (AFX.F). MERCK Kommanditgesellschaft auf Aktien (MRK.F) is trading at a lower price-to-earnings ratio than Carl Zeiss Meditec AG (AFX.F), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Carl Zeiss Meditec AG (AFX.F) and MERCK Kommanditgesellschaft auf Aktien (MRK.F)'s net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Carl Zeiss Meditec AG (AFX.F) and MERCK Kommanditgesellschaft auf Aktien (MRK.F), as reported by MarketBeat.

Carl Zeiss Meditec AG (AFX.F) currently has a consensus target price of €102.25, indicating a potential downside of 13.86%. Given Carl Zeiss Meditec AG (AFX.F)'s higher possible upside, research analysts plainly believe Carl Zeiss Meditec AG (AFX.F) is more favorable than MERCK Kommanditgesellschaft auf Aktien (MRK.F).

Dividends

Carl Zeiss Meditec AG (AFX.F) pays an annual dividend of €0.65 per share and has a dividend yield of 0.5%. MERCK Kommanditgesellschaft auf Aktien (MRK.F) pays an annual dividend of €2.60 per share and has a dividend yield of 2.0%. Carl Zeiss Meditec AG (AFX.F) pays out 48.7% of its earnings in the form of a dividend. MERCK Kommanditgesellschaft auf Aktien (MRK.F) pays out 80.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Carl Zeiss Meditec AG (AFX.F) beats MERCK Kommanditgesellschaft auf Aktien (MRK.F) on 5 of the 9 factors compared between the two stocks.

Carl Zeiss Meditec AG (AFX.F) (ETR:AFX) and Sartorius (ETR:SRT) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Valuation and Earnings

This table compares Carl Zeiss Meditec AG (AFX.F) and Sartorius' top-line revenue, earnings per share (EPS) and valuation.

Carl Zeiss Meditec AG (AFX.F) has higher earnings, but lower revenue than Sartorius. Carl Zeiss Meditec AG (AFX.F) is trading at a lower price-to-earnings ratio than Sartorius, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Carl Zeiss Meditec AG (AFX.F) and Sartorius' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Carl Zeiss Meditec AG (AFX.F) and Sartorius, as reported by MarketBeat.

Carl Zeiss Meditec AG (AFX.F) currently has a consensus target price of €102.25, indicating a potential downside of 13.86%. Given Carl Zeiss Meditec AG (AFX.F)'s higher possible upside, research analysts plainly believe Carl Zeiss Meditec AG (AFX.F) is more favorable than Sartorius.

Dividends

Carl Zeiss Meditec AG (AFX.F) pays an annual dividend of €0.65 per share and has a dividend yield of 0.5%. Sartorius pays an annual dividend of €0.35 per share and has a dividend yield of 0.1%. Carl Zeiss Meditec AG (AFX.F) pays out 48.7% of its earnings in the form of a dividend. Sartorius pays out 15.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Carl Zeiss Meditec AG (AFX.F) beats Sartorius on 5 of the 9 factors compared between the two stocks.

Carl Zeiss Meditec AG (AFX.F) (ETR:AFX) and Evotec (ETR:EVT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Earnings and Valuation

This table compares Carl Zeiss Meditec AG (AFX.F) and Evotec's gross revenue, earnings per share (EPS) and valuation.

Carl Zeiss Meditec AG (AFX.F) has higher revenue and earnings than Evotec. Carl Zeiss Meditec AG (AFX.F) is trading at a lower price-to-earnings ratio than Evotec, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Carl Zeiss Meditec AG (AFX.F) and Evotec's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Carl Zeiss Meditec AG (AFX.F) and Evotec, as reported by MarketBeat.com.

Carl Zeiss Meditec AG (AFX.F) presently has a consensus target price of €102.25, indicating a potential downside of 13.86%. Evotec has a consensus target price of €29.75, indicating a potential upside of 29.12%. Given Evotec's stronger consensus rating and higher possible upside, analysts clearly believe Evotec is more favorable than Carl Zeiss Meditec AG (AFX.F).